Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Tapinarof

- PMLiVE

Lilly’s Ebglyss approved by FDA as maintenance dose for atopic dermatitis

This new option for patients allows for as few as six maintenance injections per year

- PMLiVE

Sanofi’s amlitelimab shows positive results in atopic dermatitis

Newly released study data shows consistent reductions in disease severity

- PMLiVE

Galderma’s Nemluvio rapidly relieves atopic dermatitis and prurigo nodularis symptoms

Some patients found the treatment reduced itch and sleep disturbance within just two days

- PMLiVE

Apogee Therapeutics’ atopic dermatitis candidate shows promise in phase 2 study

The inflammatory skin condition affects over 26 million people in the US

- PMLiVE

Eli Lilly/Almirall’s Ebglyss shows promise in atopic dermatitis patients with darker skin tones

The inflammatory skin condition occurs in approximately 7.3% of adults in the US

- PMLiVE

Sanofi/Regeneron share results for Dupixent in atopic dermatitis patients with darker skin tones

These are the first clinical study results for the drug in a large population of patients with darker skin tones

- PMLiVE

Galderma shares positive two-year results for Nemluvio in atopic dermatitis

The chronic inflammatory skin disease affects more than 230 million people worldwide

- PMLiVE

Organon/Henlius announce EMA validation for Perjeta biosimilar HLX11

The reference medicine holds approvals for multiple HER2-positive breast cancer indications

- PMLiVE

Amgen/Kyowa Kirin share promising phase 3 results for rocatinlimab in atopic dermatitis

The inflammatory skin disease affects up to 20% of children and 10% of adults worldwide

- PMLiVE

J&J/Protagonist’s icotrokinra shows promise in phase 3 plaque psoriasis programme

More than 125 million people worldwide are estimated to be living with the immune-mediated skin disease

- PMLiVE

Organon shares positive long-term results for Vtama cream in atopic dermatitis

The common inflammatory skin disease affects more than 26 million people in the US alone

- PMLiVE

MHRA approves Galderma’s Nemluvio to treat atopic dermatitis and prurigo nodularis

The drug has been authorised to treat patients with moderate-to-severe cases of the skin diseases

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links